Neurofibromatosis 1 News and Research

RSS

Study analyzes cancer diagnosis in children with birth defects

Scientific studies suggest that children with birth defects are at increased risk of cancer. However, it has not been assessed whether the type of cancer, the age at which they are diagnosed or the extent of cancer spread at the time of diagnosis, is different for children with birth defects compared to children without birth defects.

29 May 2020

Study finds potential new therapeutic targets for childhood brain tumors

People with the genetic condition neurofibromatosis type 1 (NF1) are prone to developing tumors on nervous system tissue.

2 May 2020

FDA approves first-ever treatment for patients with inoperable plexiform neurofibromas

The U.S. Food and Drug Administration has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).

13 Apr 2020

Study provides new insight into neurofibromin-deficient ER+ breast cancer

An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.

5 Mar 2020

Mapping genetic links between diseases using data from electronic health records

Physicians use standard disease classifications based on symptoms or location in the body to help make diagnoses. These classifications, called nosologies, can help doctors understand which diseases are closely related, and thus may be caused by the same underlying issues or respond to the same treatments.

9 Dec 2019

CTF, DELopen jointly offer unique opportunities to neurofibromatosis research community

The Children's Tumor Foundation, an innovative and global neurofibromatosis (NF) research foundation announced today a collaboration with DELopen, a DNA-encoded library technology platform sponsored by WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries.

19 Nov 2019

FDA grants acceptance to application for selumetinib as treatment for neurofibromatosis

AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).

14 Nov 2019

Researchers uncover novel molecular clues for tumor aggression in neurofibromatosis type 1

Researchers at the Johns Hopkins Kimmel Cancer Center report that their study of tumor samples from people with the rare genetic syndrome neurofibromatosis type 1 (NF1) has uncovered novel molecular clues about which tumors are most likely to be aggressive in those with NF1

From Johns Hopkins Medicine 18 Oct 2019

New grants support research on mechanics of tumor cells

At the cellular level, cancer can be viewed as a mechanical engineering challenge. The disease alters the structure and function of cells and tissues, which are meant to perform very specific tasks.

8 Oct 2019

Children's Tumor Foundation harnesses interest in rare disease research through NF Innovation Week

Neurofibromatosis, a genetic disorder that causes tumors to grow on nerves throughout the body and which affects 1 in 3,000 people - that's over 2.5 million worldwide - has no cure and few workable treatment options.

15 Sep 2019

Researchers open up possible avenue for new cancer treatments without side effects

Researchers have opened up a possible avenue for new cancer therapies that don't have the side effects that oftentimes accompany many current cancer treatments by identifying a protein modification that specifically supports proliferation and survival of tumor cells.

6 Aug 2019

Targeting immune cells could potentially treat some kinds of brain tumor, study suggests

Tumors arise when cells shake off their restraints and start to multiply out of control. But how fast a tumor grows does not depend solely on how quickly the cancer cells can divide, a new study has found.

4 Jun 2019

Children's Tumor Foundation establishes significant research initiative to combat NF2

On the occasion of World NF2 Awareness Day, the Children's Tumor Foundation has announced the establishment of a significant research initiative dedicated to finding effective treatments for NF2, along with a substantial investment of $2.3 million in this bold new effort.

23 May 2019

Study discovers origin of neurofibromas that develop throughout the skin of NF1 patients

A study published today in PLOS ONE discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with Neurofibromatosis 1.

22 May 2019

Research into cancer signaling network reveals new roadmap to tumor control

In this advanced age of molecular sleuthing, a research team led by Georgetown Lombardi Comprehensive Cancer Center have findings that suggest tumors will eventually become resistant to drug inhibitors of a common cancer pathway (dubbed YAP/TAZ), now in preclinical development.

7 May 2019

Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1

Linda Popplewell, Lecturer in Biomedical Sciences, and world-renowned Professor George Dickson, from the School of Biological Sciences, both at Royal Holloway, will lead a team looking for a treatment for NF1, a genetic disorder that causes tumors to form on nerve tissue.

20 Mar 2019

Mice sleeping fitfully help unravel mystery of insomnia

Mice that sleep fitfully could help researchers unravel the mystery of insomnia. Researchers at Washington University School of Medicine in St. Louis studied mice genetically modified to mimic the genetic disease neurofibromatosis type 1, which is associated with sleep problems.

9 Jan 2019